AbstractBackgroundArtificial intelligence–enhanced electrocardiogram (AI-ECG) analysis shows promise to predict mortality in adults with acquired cardiovascular diseases. However, its application t…
AbstractPrimary cardiac tumors are a rare disease, with 20% of the cases being malignant. Among them, angiosarcoma is characterized by a short clinical course and…
The standard strategy for TLS mitigation is dose escalation and TLS monitoring during dose ramp-up, and there is an ongoing debate on whether the standard…
AbstractBackgroundCoronary microvascular dysfunction (CMD) is a common cause of angina with no obstructive coronary artery disease (ANOCA), and effective treatment options are limited.ObjectivesThi…
High-volume disease (HVD) and low-volume disease (LVD) definitions in metastatic hormone-sensitive prostate cancer (mHSPC) patients are based on conventional imaging (CI) (CT/MRI with bone scan…
The combination in a phase II trial produced high complete response rates in patients with newly diagnosed AML.
AbstractBackgroundInfluenza virus may cause severe infection in patients with heart failure. It is known that influenza infection is associated with increased morbidity and mortality in…
Researchers studied outcomes of transplant recipients who received kidneys from toxoplasma-positive versus negative donors.
Dr. Adewole Adamson discusses the stable mortality amid growing pancreatic cancer cases, and how some cases of pancreatic cancer are misattributed as early-stage endocrine cancer.
In a roundtable discussion, experts discuss important abstracts from ASH 2024 and how the research may impact future treatment of myelofibrosis.
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to sacituzumab govitecan-hziy (Trodelvy®) for extensive-stage small cell lung cancer.
